



FOR IMMEDIATE RELEASE

Date: 16 September, 2013

InteRNA Technologies also receives notice of allowance for its melanoma lead compound miRNA-3157 in Australia

Nijmegen/Utrecht (the Netherlands) – InteRNA Technologies B.V., a biopharma company engaged in the development of microRNA (miRNA)-based therapeutics for oncology, announces that following the notice of allowance of the United States Patent and Trademark Office (USPTO) last year, the Australian Patent Office now also has issued the Company a notice of allowance on the patent application covering miRNA sequences, identified through deep sequencing of several different mouse, monkey and human samples, including different tumor samples. Also here, the allowable product claims protect miRNA-3157, homologues, precursors and mimics thereof. A mimic of miRNA-3157 is in preclinical development and represents InteRNA's lead product in its B-Raf/melanoma program.

"We are very pleased with this issuance in Australia, the continent which has the highest incidence rate of melanoma, and more importantly, the highest death rates from melanoma worldwide. It further strengthens our intellectual property position and allows us to remain focused on the further development of our lead compound to the clinic to address the high medical need of this cancer", said Roel Schaapveld, CEO of InteRNA Technologies.

Melanoma is one of the few cancer indications of which the incidence and mortality rates are still growing, according to a January 2013 special report by the US National Cancer Institute.

The latest data on miRNA-3157 as drug candidate for the treatment of human melanoma will be presented at the Society for Melanoma Research 2013 Congress, November 17-20 in Philadelphia, PA, USA.

About InteRNA Technologies B.V.

InteRNA Technologies develops cancer therapeutics based on a broadly applicable proprietary technology platform for the rapid identification and validation of therapeutic miRNAs. The Company has exclusive access to one of the largest miRNA libraries in the world. At present, InteRNA has established in vivo proof of concept for multiple pipeline candidates. The Company is pursuing a proactive partnership strategy to acquire appropriate delivery technologies for its products and expects to engage in corporate partnerships to progress several of its products into clinical development.

InteRNA Technologies was incorporated in December 2006 by Aglaia Oncology Fund as a spin-off from the Hubrecht Institute, Utrecht, the Netherlands.

See for more information www.interna-technologies.com.



Contact:

Roel Schaapveld, PhD, MBA
CEO
InteRNA Technologies B.V.

Corporate office
Nijmegen City Centre
Jonkerbosplein 52
6534 AB Nijmegen
The Netherlands

Phone: +31 (0)24 352 96 33 / +31 (0)30 2532386
E-mail: schaapveld@interna-technologies.com